New York, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Isolation/Cell Separation Market by Product, Cell Type, Cell Source, Technique, Application, End-User - Global Forecast to 2025" - https://www.reportlinker.com/p04315097/?utm_source=GNW With the rising focus on the development of personalized medicine, the number of personalized medications available in the market has steadily increased over the last decade, and this trend is expected to continue in the coming years.

The consumablesaccounted for the highest growth rate in thecell isolationmarket, by productduring the forecast periodBased on product, the cell isolation market is segmented into consumables and instruments.The consumables segment accounted for the largest share in the cell isolation market in the forecasted period.

The increasing investments by companies to develop technologically advanced products as well as the repetitive use of consumables as compared to instruments are the major factors driving the growth of this segment.

Human cells segment accounted for the highest CAGRBased on cell type, the cell isolation market is segmented into human cells and animal cells.The human cells segment accounted for the largest share of the global cell isolation market in the forecasted period.

The increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the high and growing incidence of diseases such as cancer are the major factors driving this segments growth.

Biotechnology and biopharmaceutical companiessegment accounted for the highest CAGRThe cell isolation market is segmented into hospitals and diagnostic laboratories, biotechnology and biopharmaceutical companies, research laboratories and institutes, and other end users based on end users.In 2019, the biotechnology and biopharmaceutical companies segment accounted for the largest share.

The widespread adoption of advanced instruments in cell-based experiments and cancer research in biotechnology and biopharmaceutical companies, as well as the increasing number of R&D facilities globally are the major factors driving this segments growth.

Asia Pacific: The fastest-growing regioncell isolation marketThe global cell isolation market is segmented into North America, Europe, Asia Pacific, and Rest of the world.The Asia Pacific region is projected to register the highest CAGR during the forecast period.

Growth in this region is expected to be centered on China and Japan. Factors such as the expansion by key market players in emerging Asian countries and the increasing trend of pharmaceutical outsourcing to Asian countries like India and China are driving the growth of the cell isolation market in this region.

The primary interviews conducted for this report can be categorized as follows: By Company Type: Tier 1 - 20%, Tier 2 - 45%,and Tier 3 -35% By Designation: C-level - 30%, D-level - 20%, and Others - 50% By Region: North America -35%, Europe - 24%, Asia Pacific - 25%, Rest of the world 16%

Lits of Companies Profiled in the Report: Thermo Fisher Scientific, Inc. (US) Becton, Dickinson and Company Limited (US) Beckman Coulter Inc. (US).Merck KGaA (Germany) Terumo BCT (Japan), GE Healthcare (US) Bio- Rad Laboratories Inc. (US) Corning Inc. (US) Roche Diagnostics (Switzerland) Alfa Laval (Sweden) Miltenyl Biotech (Germany) pluriSelect Life Science (Germany) STEMCELL Technologies Inc. (Canada) Akadeum Life Sciences, Inc (US) Bio- Techne (US), Bio Legend (US) Invent Biotechnologies (US)

Research Coverage:This report provides a detailed picture of the global cell isolation market.It aims at estimating the size and future growth potential of the market across different segments, such as product, celltype, cell source, technique, application, end user, and region.

The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell isolation market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the markets pulse and provide them with information on the key market drivers, restraints, trends, and opportunities.

Read the full report: https://www.reportlinker.com/p04315097/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% - GlobeNewswire

The 62 rating InvestorsObserver gives to Akero Therapeutics Inc (AKRO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, AKROs 62 overall rating means the stock scores better than 62 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Akero Therapeutics Inc (AKRO) stock has gained 3.4% while the S&P 500 is lower by -0.22% as of 3:14 PM on Tuesday, Dec 22. AKRO has gained $0.87 from the previous closing price of $25.62 on volume of 255,146 shares. Over the past year the S&P 500 is higher by 14.35% while AKRO has gained 21.96%. AKRO lost -$2.16 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Akero Therapeutics Inc (AKRO) Stock.

Read the original:
Where Does Akero Therapeutics Inc (AKRO) Stock Fall in the Biotechnology Field? - InvestorsObserver

IT has been nearly two decades since the Philippine government approved the sale and cultivation of genetically modified (GM) corn seeds in local farms. The government issued a permit to commercialize Monsanto Philippiness bacillus thuringiensis (Bt) corn variety dubbed YieldGard on December 5, 2002. With this, the Philippines earned the distinction of being the first in Asia to commercialize Bt corn, a variety that enables corn farmers to save on production cost because they will no longer have to extensively use pesticides to kill the corn borera grain pest, particularly of corn.

Bt corn has been largely instrumental in increasing farmers production in the ensuing years following the issuance of the permit to Monsanto. The increment in output allowed the Philippines to become self-sufficient in corn (See, Yellow corn yield achieved 103 percent self-sufficiency last yearPiol, in the BusinessMirror, March 28, 2018). With the help of the biotech product, farmers were able to earn $642 million from 2003 to 2015, according to the International Service for the Acquisition of Agri-biotech Applications.

Its advantages and its potential to boost incomes have encouraged more farmers to plant the variety in recent years. The United States Department of Agricultures Foreign Agricultural Service in Manila noted that areas planted with Bt corn in the Philippines expanded by 26 percent to 834,617 hectares this year (See, Gain report: GE corn areas in PHL continue to expand, in the BusinessMirror, November 30, 2020). The availability of more yellow corna raw material used in manufacturing animal feedshas also supported the growing livestock and poultry industry.

These developments illustrate the benefits of biotechnology as well as its potential to enable the Philippines to develop other products that will allow farmers to diversify to other crops as well as cope with the ill effects of climate change. Currently, Bt corn is the only biotech product that is being planted in the Philippines. The GM varieties of other crops, like eggplant, are in various stages of development.

It is also worth noting that the Bt corn variety that was approved for commercialization in 2002 was made in the United States. The Philippines has yet to develop its own GM crop, and we urge Philippine researchers and scientists to make biotech products that are tailor fit to local conditions. Government must support these efforts by putting more money in the research initiatives of our local scientists or introduce policies, such as incentives, that will encourage the private sector to partner with them.

The recent successive typhoons that struck the Philippines should serve as a stark reminder of the increasing difficulties being faced by Filipino farmers and the pressing need for government to look for more sustainable means of ensuring food security. We welcome the Department of Agricultures (DA) pronouncement that it will optimize the use of biotechnology and other science-based solutions to increase farm output from limited farmlands and fishing grounds.

We urge Congress to support the DAs initiatives by passing the proposed Modern Biotechnology Act and by increasing the budget for agricultural research and development. Fully supported, our own scientists can harness the power of modern biotechnology.

Read more:
Reaping the promise of biotechnology - Business Mirror

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market(NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology IndexSMFund. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Ovid Therapeutics

Ovid Therapeutics Inc.is aNew York-based biopharmaceutical company using its BoldMedicineapproach to develop medicines that transform the lives of patients with rare neurological disorders. The Company is developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited, which is expected to initiate its pivotal clinical trials in 2021 for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). OVID is evaluating the results of the NEPTUNE trial of OV101 (gaboxadol) for the treatment of Angelman syndrome and Fragile X syndrome. For more information on Ovid, please visitwww.ovidrx.com.

Contacts

Investors and Media:Ovid Therapeutics Inc.Investor Relations & Public Relationsirpr@ovidrx.com

OR

Investors:Argot PartnersMaeve Conneighton/Dawn Schottlandt212-600-1902ovid@argotpartners.com

Media:Dan Budwick1ABdan@1abmedia.com

Continue reading here:
Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index - GlobeNewswire

Sutro Biopharma Inc (STRO) is near the top in its industry group according to InvestorsObserver. STRO gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Sutro Biopharma Inc gets a 81 rank in the Biotechnology industry. Biotechnology is number 35 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Sutro Biopharma Inc (STRO) stock is trading at $16.67 as of 12:19 PM on Thursday, Dec 3, a gain of $0.32, or 1.96% from the previous closing price of $16.35. The stock has traded between $16.23 and $17.59 so far today. Volume today is 309,465 compared to average volume of 322,449.

Click Here to get the full Stock Score Report on Sutro Biopharma Inc (STRO) Stock.

Go here to see the original:
Is Sutro Biopharma Inc (STRO) the Top Pick in the Biotechnology Industry? - InvestorsObserver

The 60 rating InvestorsObserver gives to Kazia Therapeutics Ltd (KZIA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, KZIAs 60 overall rating means the stock scores better than 60 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Kazia Therapeutics Ltd (KZIA) stock is trading at $11.12 as of 1:21 PM on Friday, Nov 20, a drop of -$0.88, or -7.33% from the previous closing price of $12.00. The stock has traded between $10.52 and $11.99 so far today. Volume today is 863,594 compared to average volume of 726,043.

Click Here to get the full Stock Score Report on Kazia Therapeutics Ltd (KZIA) Stock.

See the original post here:
Is Kazia Therapeutics Ltd (KZIA) The Right Choice in Biotechnology? - InvestorsObserver

FAISALABAD: National Institute for Biotechnology and Genetic Engineering (NIBGE) Director General Dr Shahid Mansoor Friday said first Biotechnology Park of Pakistan will be established in M-3 industrial city, Faisalabad.

During his visit to the Faisalabad Chamber of Commerce & Industry (FCCI), he said the government is also mulling to setup proposed National University of Bio-sciences to avail the existing expertise of Nuclear Institute for Agriculture & Biotechnology (NIAB) and the NIBGE.

He said cutting edge biotechnology has gained importance in almost all segments of economy. Regarding Biotechnology Park, he said NIBGE has 12 acres of land in M3 Industry city near Sahianwala interchange.

Its scientists will provide Research and Development facilities while businessmen in general and young entrepreneurs in particular will commercialize new and innovative technologies.

He said the FCCI should work closely with NIBGE and take responsibility to finance different pilot projects based on new and workable ideas.

Explaining the achievements of the NIBGE, he said it has introduced the innovative idea of floating gardens to recycle the industrial effluent. These floating gardens are being successfully used in Chakera water treatment ponds by Water And Sanitation Agency (WASA), he maintained.

He said this facility could also be provided for Paharang and Maduaana drains passing from the western and eastern side of the city. These floating gardens will treat the waste water before its safe discharge into the nearby river, he said and added that it will not pollute the river water and thus play an instrumental role in saving aquatic life. He further said that treated water of these drains could also be used for irrigation purposes in the water starved areas of the region.

FCCI senior vice president Chaudhry Talat Mahmood appreciated the role of NIAB and NIBGE in the overall development of the country and said our main issue is dissemination of innovative technology at the gross root level and in this connection the FCCI and NIBGE should ink a Memorandum Of Understanding (MOU). Executive Member Dr. Sajjad Arshad said Pakistan is importing vaccines for poultry birds from Egypt.

NIBGE must prepare this vaccine locally to save the precious foreign exchange, he added. The meeting was also attended by Dr Habib Aslam Gaba and other executive members of the FCCI.

Original post:
Biotechnology Park to be established in Faisalabad - The News International

How far off is Universal Vision Biotechnology Co., Ltd. (GTSM:3218) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the forecast future cash flows of the company and discounting them back to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

View our latest analysis for Universal Vision Biotechnology

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = NT$10.0b

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 0.9%. We discount the terminal cash flows to today's value at a cost of equity of 6.6%.

Terminal Value (TV)= FCF2030 (1 + g) (r g) = NT$1.7b (1 + 0.9%) (6.6% 0.9%) = NT$31b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= NT$31b ( 1 + 6.6%)10= NT$16b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is NT$26b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of NT$286, the company appears about fair value at a 17% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Universal Vision Biotechnology as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.6%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Universal Vision Biotechnology, we've put together three further elements you should further research:

PS. Simply Wall St updates its DCF calculation for every Taiwanese stock every day, so if you want to find the intrinsic value of any other stock just search here.

PromotedIf you decide to trade Universal Vision Biotechnology, use the lowest-cost* platform that is rated #1 Overall by Barrons, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

The rest is here:
Estimating The Fair Value Of Universal Vision Biotechnology Co., Ltd. (GTSM:3218) - Simply Wall St

Hyderabad-based Bharat Biotech International Ltd (BBIL) on Friday said it would manufacture 10 types of vaccines including Malaria and Covid- 19 in its upcoming unit in Odisha.

BBIL Chairman and Managing Director Dr Krishna Ella said this while attending a meeting through digital mode with Odisha chief secretary A K Tripathy and other state government officials.

BBIL is a multi-dimensional biotechnology organisation specializing in manufacture of vaccines and bio-therapeutics, Ella said.

The company has taken up the development and production of new or improved vaccines against severe Rotavirus Diarrhoea, Malaria, Japanese Encephalitis, Rabies, Pandemic Influenza and drug resistant Staphylococcus aureus, he said.

In BBILs unit at Andharua of Bhubaneswar, the company would produce 10 types of vaccines including malaria and Covid-19, he said, adding that the total investment would be around Rs 300 crore.

Best of the technology will be put in the Odisha unit, the BBIL chief said.

The chief secretary assured BBIL that the state government would provide all support for future expansion of the unit at Andharua in Bhubaneswar.

Tripathy also directed the authorities to start the ground level construction work within a fortnight and commence production within the scheduled time.

The chief secretary also asked the BBIL to set up a state of art biotech incubation center, common facilities and IT corridor along with the first phase construction of the industry.

The company was also requested to promote the local start-ups.

Secretary Skill Development and Technical Education and Chairman & Managing Director IDCO SK Singh said: Land is readily available at Biotech Park, Andharua for groundbreaking works. The building plan as per the design has also been approved.

Principal Secretary Science and Technology S Sadangi said: the required statutory clearances and pollution control board permission has been availed for setting up the unit.

Read more:
Bharat Biotech to manufacture 10 types of vaccines, including Covid-19, at Odisha unit - Hindustan Times

NEW YORK (PRWEB) November 03, 2020

The Healthcare Technology Report is pleased to announce The Top 25 Women Leaders in Biotechnology of 2020. These accomplished women have led a wide range of initiatives supporting the development of treatments for complex diseases and other illnesses. In light of the current pandemic, some have also provided guidance, through their high-level roles, toward the research and development of treatments that will ultimately curb the spread of COVID-19. Overall as a group, their business expertise, clinical acumen, strategic decision making, and overall passion for creating medicines to heal others has led them to consistently achieve and thrive in an ever evolving industry.

The women recognized on this years list have contributed to major growth and development within their companies. For example, Angela Hwang is the Group President of Pfizers Biopharmaceutical Group the division which comprises 80% of Pfizers revenue. She leads 26,000 colleagues in bringing over 600 products and medicines to patients and aided the group in achieving approximately $40 billion in revenue last year. Furthermore, two companies saw multiple awardees; GRAIL, Inc. and STEMCELL Technologies each had two awardees on this years list, demonstrating the impact that a strong corporate culture can have in producing leaders.

Through the depth and breadth of their knowledge, as well as their ability to lead highly efficient teams, these women stand out as role models for the next generation of women in healthcare and biotechnology. Please join The Healthcare Technology Report Team in celebrating the achievements of The Top 25 Women Leaders in Biotechnology of 2020.

Angela Hwang (Pfizer), Andrea Wainer (Abbott), Ginger Gregory (Biogen), Kimberly Smith (ViiV Healthcare), Joan Sheehan (STEMCELL Technologies), Helen Sheridan (STEMCELL Technologies), Lee Ann Kimak (Bavarian Nordic), Sheila Gujrathi (Gossamer Bio), Angela Huskey (Millennium Health), Alice Chen (GRAIL, Inc.), Marissa Lee Song (GRAIL, Inc.), Cynthia Pointer (ArcherDX), Heather Steinman (The Wistar Institute), Pia Olson (Ora, Inc.), Anne Jones (Genuity Science), Christiane Buisson (Cerba Research), Natalie Bartlett (ZAGENO), Dalia Argaman (EarlySense), Jennifer Burdman (PolarityTE), Irina Sher (Bioforum), Priya Mande (PsiOxus Therapeutics), Li Xu (Transcenta), Laura Ayala (Karius), Terry Crandall (Ironshore Pharmaceuticals), and Veronica Hughes (US HealthVest).

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on healthcare technology and the various companies, executives and investors that make up the sector.

Share article on social media or email:

Read more:
The Top 25 Women Leaders in Biotechnology of 2020 - PR Web

KISUMU, Kenya, Nov 5 Kenya Agricultural and Livestock Research Organization plans to introduce Biotechnology Maize (Bt Maize) to farmers in the next three years to reduce yield losses caused by fall armyworms and stalk borer.

KALRO Director-General Dr. Eliud Kireger told journalists in Kisumu that research on Bt Maize is at an advanced stage, with plans of introducing it in the Kenyan market in 2023.

According to the Director-General, the trials by KALRO show that Bt Maize effectively controls maize infestation and damage by the two major pests affecting maize production in the country.

He added that once the new variety is approved by the government, it will help in addressing losses incurred as a result of the pests.

The new variety being developed in South Africa will be in stores to help farmers fight fall armyworms and stalk borer, he said.

Researchers believe that Bt Maize will directly contribute to the countrys national aspirations and goals of improving the agricultural sector through the use and adaptation of appropriate technologies to address national food security.

Read more:
Biotechnology Maize to be Introduced in Kenya by 2023 - Capital FM Kenya

The Global Agricultural Biotechnology Market report, published by Verified Market Research, is an extensive compilation of the essential aspects of the global Agricultural Biotechnology market, assessed thoroughly by our team of researchers. The market intelligence report offers insightful data and information relevant to the market to acquaint the readers with the lucrative growth prospects existing in this industry, eventually helping them formulate effective business strategies. The global Agricultural Biotechnology market report has been methodically curated using industry-verified data to offer information concerned with the leading manufacturers and suppliers engaged in this sector. It further focuses on their pricing analysis, gross revenue, product portfolio, sales network & distribution channels, profit margins, and financial standing.

Agricultural Biotechnology Market was valued at USD 35.6 Billion in 2018 and is projected to reach USD 74.92 Billion by 2026, growing at a CAGR of 9.70% from 2019 to 2026.

Get a sample of the report @ https://www.verifiedmarketresearch.com/download-sample/?rid=35624

Competitive Landscape:

The global Agricultural Biotechnology market is highly consolidated due to the presence of a large number of companies across this industry. The report discusses the current market standing of these companies, their past performances, demand and supply graphs, production and consumption patterns, sales network, distribution channels, and growth opportunities in the market. Moreover, it highlights the strategic approaches of the key players towards expanding their product offerings and reinforcing their market presence.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The report further sheds light on the various strategic business initiatives undertaken by the key market contenders to fortify their foothold in this business sector. These strategies majorly include mergers & acquisitions, partnerships & collaborations, joint ventures, government and corporate deals, brand promotions, new product launches, and numerous others. In the later part of the report, the major components of the Agricultural Biotechnology industry, such as product type, application gamut, end-use industries, and the solutions and services offered by the leading manufacturers, have been analyzed. Numerical data and subjective information pertaining to each market segment have been featured in the report for better understanding.

Therefore, the latest research document includes competitive analysis, key market players, crucial industry-related facts & figures, sales revenue, product prices, gross margins, market shares, business strategies, dominant regions, and key developments.

Agricultural Biotechnology Market, By Organism Type

Plants Animal Microbes

Agricultural Biotechnology Market, By Application

Vaccine Development Transgenic Crops & Animals Antibiotic Development Nutritional Supplements Flower Culturing Biofuels

Request a discount on the report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=35624

The report encompasses the significant effects of the coronavirus pandemic on the Agricultural Biotechnology market and its key segments. The report offers a vivid picture of the current market scenario, closely investigating the impact of the pandemic on this specific business sphere, its leading players, supply chains, distribution channels, and its global scenario. The pandemic has affected the global industry extensively, subsequently disrupting the Agricultural Biotechnology market mechanism. Furthermore, the research study examines the Agricultural Biotechnology market and the recent disruptive changes in the business setting that followed the outbreak. Also, the future effects of the pandemic on the market have been assessed in the report.

Key Geographies Encompassed in the Report:

North America (U.S., Canada)Europe (U.K., Germany, Italy, France, Rest of EU)Asia Pacific (India, Japan, China, Australia, Rest of APAC)Latin America (Brazil, Argentina, Rest of Latin America)Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Market Taxonomy:

Chapter 1: Methodology & Scope

Definition and forecast parametersMethodology and forecast parametersData Sources

Chapter 2: Executive Summary

Business trendsRegional trendsProduct trends

Chapter 3: Industry Insights

Industry segmentationIndustry landscapeVendor matrixTechnological and innovation landscape

Chapter 4: Regional Landscape

Chapter 5: Competitive Outlook

Company ProfileBusiness OverviewFinancial DataProduct LandscapeStrategic Outlook

To read more about the report, visit @ https://www.verifiedmarketresearch.com/product/agricultural-biotechnology-market/

Advantages of the Agricultural Biotechnology Market Report:

The report offers a clear description of the global Agricultural Biotechnology market, containing the current market growth inclinations and future estimations to help businesses identify the potential investment areas.

The report covers the major market growth drivers, and constraints, alongside an extensive COVID-19 impact analysis.

The all-inclusive market feasibility reveals the profit-making trends to obtain a powerful foothold in the Agricultural Biotechnology industry.

The SWOT analysis and Porters Five Forces Analysis explicate the effectiveness of the customers and providers from a global perspective.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Follow this link:
Agricultural Biotechnology Market Size | Incredible Possibilities and Growth Analysis and Forecast To 2027 - Eurowire

Predicting Growth Scope: Global Biotechnology/ Pharmaceutical Services Outsourcing Market

Unbiased research initiatives offer relevant cues on the impressive market recovery from a sudden pandemic crisis that substantially laid a temporary dent in the Global Biotechnology/ Pharmaceutical Services Outsourcing Market . Proceeding further, this extensive research compilation suggests that the CAGR percentage is anticipated to be on an optimistic prognosis, reflecting impressive revenue generation outcomes through the forecast span. Echoing lucrative growth outcome of the historical timeline, future growth possibilities are also likely to remain robust in foreseeable future.

This report on global Biotechnology/ Pharmaceutical Services Outsourcing market is designed to serve as a ready-to-use guide for developing accurate pandemic management programs allowing market players to successfully emerge from the crisis and retrack voluminous gains and profits.

Competition Spectrum:Our in-house research professionals have heavily relied upon primary and secondary research practices and methodologies to derive deductions.

which market players and aspiring new entrants may witness seamless entry.

Quantic GroupQuintilesIMSParexel International CorporationLachman AssociatesGMP PharmaceuticalsManagement ForumQuality ContextInspired PharmaConcept Heidelberg GmbHRSSL

This versatile research report presentation on global Biotechnology/ Pharmaceutical Services Outsourcing market through its market demonstration efforts further presents insightful detailing about both qualitative and quantitative valuation of the global Biotechnology/ Pharmaceutical Services Outsourcing market, incorporating details about competition developments and strides, vendor positioning as well as future-ready monetary policy making to ensure steady growth and sustainability of the players. All the profiled vendors have been assessed to comprehend growth favoring investments.

Aligning with reader preferences for thoughtful business analysis, this report on global Biotechnology/ Pharmaceutical Services Outsourcing market also categorizes the market into significant segments.

Find full report and TOC here: @ https://www.orbismarketreports.com/global-biotechnology-pharmaceutical-services-outsourcing-market-analysis-by-growth-and-forecast-2025?utm_source=PujaM

The market is roughly segregated into:

Analysis by Product Type: The report includes in-detail references of all the notable product categories as well as application specifications. The product segment is described on the basis of key player development traits, sales overview, volume based returns and the like.ConsultingAuditing & AssessmentRegulatory AffairsProduct MaintenanceProduct Design & DevelopmentProduct Testing & ValidationTraining & EducationOthers

Application Analysis: Global Biotechnology/ Pharmaceutical Services Outsourcing market also specifically underpins end-use application scope and their improvements based on technological developments and consumer preferences.Regenerative MedicineBiobankingDrug Discovery

Segmentation by Region with details about Country-specific developments North America (U.S., Canada, Mexico) Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS) Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific) Latin America (Brazil, Rest of L.A.) Middle East and Africa (Turkey, GCC, Rest of Middle East)

Crucial Takeaways: Global Biotechnology/ Pharmaceutical Services Outsourcing Market

Committed to offer real time data on ongoing market developments and trends, this detailed research report on global Biotechnology/ Pharmaceutical Services Outsourcing market also entails a clear and detailed overview of the Biotechnology/ Pharmaceutical Services Outsourcing market amidst the global pandemic and the various pandemic management operation designed and implemented by frontline and contributing players alike.

The report particularly zooms in to find the prominent market alterations affecting global Biotechnology/ Pharmaceutical Services Outsourcing market in a multi-dimensional scheme encompassing production and consumption patterns, CAGR percentage, pricing alteration, besides lending significant awareness upon evident challenges, threats, development cycles.

The report includes detailed market overview inclusive of details in the historical and current timelines. The report scouts for noteworthy trends and profit generation trends in the past decades, followed by current status.

The multi-timeline Biotechnology/ Pharmaceutical Services Outsourcing market analysis is in place to allow market players devise growth-oriented business strategies and tactical decisions, thus securing healthy growth trail and profit numbers in the foreseeable future.

Relevant details on prevalent market competition and rising intensity with inclusion of new market players also find ample mention in the report to evoke wise comprehension and appropriate growth related business strategies, favoring strong competitive edge. Details on technological innovation, and inputs on M&A developments, commercial agreements have all been touched upon in this illustrative research report on the Biotechnology/ Pharmaceutical Services Outsourcing market.

Do You Have Any Query or Specific Requirement? Ask Our Industry [emailprotected] https://www.orbismarketreports.com/enquiry-before-buying/135312?utm_source=PujaM

Customization Service of the Report:-Orbis Market Reports Analysis gives customization of Reports as you want. This Report will be customized to satisfy all of your necessities. For those who have any query get in contact with our sales staff, who will assure you to get a Report that fits your requirements.

Looking for provoking fruitful enterprise relationships with you!

About Us :

With unfailing market gauging skills, has been excelling in curating tailored business intelligence data across industry verticals. Constantly thriving to expand our skill development, our strength lies in dedicated intellectuals with dynamic problem solving intent, ever willing to mold boundaries to scale heights in market interpretation.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

See the original post:
Global Biotechnology/ Pharmaceutical Services Outsourcing Market Expected to reach highest CAGR in forecast period :Quantic Group, QuintilesIMS,...

One of the issues that attracted agreement at the conference was the need to unite efforts regarding the dissemination of the benefits of plant biotechnology and the improvement of the regulatory aspects of its use in our country.

Science is a great ally in reaching agreements on possible ways to combat the effects of climate change. phrase from Carolina UrmenitaAnd Head of the Climate Change Office at the Ministry of Environment, summarizes the consensus among the speakers and speakers at the symposium Science, Agriculture and Climate Crisis, regarding the role that appropriate dissemination and linkage by the scientific world can play, to inform authorities, decision-makers and public opinion in general, of the potential that biotechnology can have, in the context of plant genetic improvement, as one of the options for addressing the challenges posed by climate change to agriculture Today.

Greetings from Alvaro Izaguirre, Executive Director of the Foundation for Agricultural Innovation, FIA, of the Ministry of AgricultureInitiated a symposium organized by ChileBio in which prominent national and international scholars and publishers participated, demonstrating various advances in Biotechnology for better food. Eyzaguirre commented: Science and agriculture must work together to make it more effective. This discipline plant biotechnology can be a strategic ally in the production of staple foods, commented. It is important for scientific communication to raise debate about the benefits of using these tools, especially when climate change is showing its effects, he added.

In this international symposium, the participation of the famous and famous scientist came to the fore. Jos Miguel Mollet, Chemistry Graduate and Ph.D. in Biochemistry and Molecular Biology from the University of ValenciaProfessor, Department of Biotechnology at the Polytechnic University of Valencia. He published a series of books and several articles in the press. He also highlighted the post Gabriel LyonAnd Chilean scientist, biochemist and physician in cell and molecular biology. A science communicator and author of popular science books such as Pop Science, What are snot? And Other Weird Questions I Sometimes Ask, among others.

Subsequently, a panel discussion was developed to which he joined Carolina Urmenita, Head of Climate Change Office at the Ministry of Environment and Francesca Castillo, Academician at Austral University in Chile and member of Agrupacin por la Biotecnologa y la Sostenibilidad Agroalimentaria (ABSA Chile), An exciting exchange of ideas, reflections and experiences on the role of plant biotechnology has developed.

Speakers have commented extensively on the difficulty of getting the message across from science that turns to evidence, in a world where emotion and shock seem to have more access to public opinion. Besides, they stressed the need for progress in Chile in organizing that allows us to use developments in the genetic improvement of vegetables in our cultivation, and to reach commercial stages, where today there is still an important crossroads.

CEO of ChileBIOAnd Miguel Angel Sanchez, He commented on the outcome of this meeting: It was a symposium that addressed the topics necessary to understand, discuss and look to the future regarding plant biotechnology. Both of them are of the necessity of communicating about the role of the various tools they possess, through misinformation and ignorance of their benefits. Climate change is here to stay, and the challenge of food production will increase to pursue Food security pathway. The development of plant varieties that are better adapted to climatic challenges, such as drought and heat tolerance and resistance to certain pests and diseases is a reality in the scientific world, he says.

One of the issues that attracted agreement at the conference was the need to unite efforts regarding the dissemination of the benefits of plant biotechnology and the improvement of the regulatory aspects of its use in our country. Sanchez concludes, There is a consensus in the scientific world about all the attributes of the different tools that biotechnology gives us, but there is an opinion of the public that views them with suspicion.. Gabriel Leon added: There is a schizophrenia between science and public opinion and this feeling has a very big impact.

Committee members agreed on the regulatory aspects that Chile needed to resolve in order for biotechnology solutions to be available for local production. On his part, he commented, Valuing biotechnology and making it available to small farmers is a viable path, in addition to creating an institutional framework that supports it. Dr. Francesca Castillo, researcher at the University of Austral and a spokesperson for the Association for Biotechnology and Food Sustainability (ABSA-Chile) who also stressed that there has to be a political will to sit down and discuss biotechnology, because its not all about genetics.

Read more from the original source:
A symposium entitled "Science, Agriculture and Climate Crisis", which highlighted the role of plant biotechnology in adapting agriculture to...

The 66 rating InvestorsObserver gives to Diffusion Pharmaceuticals Inc (DFFN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 83 percent of stocks in the Biotechnology industry, DFFNs 66 overall rating means the stock scores better than 66 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Diffusion Pharmaceuticals Inc (DFFN) stock is lower by -6.29% while the S&P 500 has risen 0.93% as of 2:05 PM on Tuesday, Jan 19. DFFN is down -$0.07 from the previous closing price of $1.13 on volume of 2,697,020 shares. Over the past year the S&P 500 has risen 14.53% while DFFN has risen 112.00%. DFFN lost -$0.49 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Diffusion Pharmaceuticals Inc (DFFN) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the original post:
Is Diffusion Pharmaceuticals Inc (DFFN) The Right Choice in Biotechnology? - InvestorsObserver

LOWELL, Mass., Oct. 25, 2021 /PRNewswire/ -- Alcyone Therapeutics ("Alcyone"), a biotechnology company developing precision therapies for neurological disorders with high unmet medical needs, today announced four key appointments to its executive leadership team, bringing significant expertise in neuroscience and genetic medicines development. Alcyone Therapeutics appointed Ottavio Vitolo, M.D., M.M.Sc., Chief Medical Officer and Global Head of R&D; Ravi Mehrotra, Ph.D., Chief Financial Officer and Head of Strategy; Susan D'Costa, Ph.D., Executive Vice President & Global Head of Technology; and Rachel Salzman, D.V.M., Executive Vice President of Portfolio, External Affairs & Development.

"I am thrilled to welcome Ottavio, Ravi, Susan and Rachel to Alcyone's executive management team. They are all accomplished leaders who bring diverse and vast expertise in the development of novel treatments for neurological disorders, in particular precision genetic therapies. They also all share the mission to build Alcyone into a premier organization that will bring transformative medicines to patients in need of better treatment options," said PJ Anand, Founder and Chief Executive Officer of Alcyone Therapeutics. "They will be integral to building our future as a leader in the development of central nervous system (CNS) therapies through a uniquely integrated, multi-disciplinary approach, as we leverage our FalconTM precision dosing technology and our multiple genetic therapy platforms."

About Alcyone TherapeuticsAlcyone Therapeutics is a biotechnology company developing precision therapies for neurological disorders with high unmet medical needs. The company integrates innovation in neuroscience, precision dosing platforms and in-house manufacturing capabilities to deliver transformative therapies to patients. Alcyone leverages the synergy between FalconTM, the company's proprietary intrathecal precising dosing platform that incorporates deep knowledge of CSF fluid dynamics, computational modeling and bioengineering, and multiple novel genetic therapy platforms developed at the Abigail Wexner Research Institute at Nationwide Children's Hospital (AWRI). This comprehensive approach allows for the optimization of central nervous system (CNS) dosing and delivery to better target the pathophysiology and anatomy specific to various neurological disease areas. Alcyone's lead programs target the treatment of Rett syndrome and IGHMBP2-Related Diseases (IRD). For more information, visit https://alcyonetx.com/, and follow Alcyone on LinkedIn and Twitter.

SOURCE Alcyone Therapeutics

Read the original:
Alcyone Therapeutics Strengthens Executive Team with New Senior Leadership Appointments - PRNewswire

BioXcel Therapeutics Inc (BTAI) is around the top of the Biotechnology industry according to InvestorsObserver. BTAI received an overall rating of 85, which means that it scores higher than 85 percent of all stocks. BioXcel Therapeutics Inc also achieved a score of 98 in the Biotechnology industry, putting it above 98 percent of Biotechnology stocks. Biotechnology is ranked 26 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

BioXcel Therapeutics Inc (BTAI) stock is lower by -3.89% while the S&P 500 is up 0.33% as of 3:19 PM on Friday, Jan 8. BTAI is down -$2.14 from the previous closing price of $54.95 on volume of 485,305 shares. Over the past year the S&P 500 is higher by 16.55% while BTAI is up 330.75%. BTAI lost -$3.37 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BioXcel Therapeutics Inc (BTAI) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Go here to read the rest:
Is BioXcel Therapeutics Inc (BTAI) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Ionis Pharmaceuticals Inc (IONS) is near the bottom in its industry group according to InvestorsObserver. IONS gets an overall rating of 26. That means it scores higher than 26 percent of stocks. Ionis Pharmaceuticals Inc gets a 15 rank in the Biotechnology industry. Biotechnology is number 30 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 26 means the stock is more attractive than 26 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Ionis Pharmaceuticals Inc (IONS) stock has fallen -0.68% while the S&P 500 has risen 0.09% as of 12:10 PM on Thursday, Dec 24. IONS has fallen -$0.41 from the previous closing price of $60.27 on volume of 784,407 shares. Over the past year the S&P 500 is up 13.99% while IONS has fallen -2.62%. IONS earned $0.49 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 121.29.

Click Here to get the full Stock Score Report on Ionis Pharmaceuticals Inc (IONS) Stock.

Visit link:
Is Ionis Pharmaceuticals Inc (IONS) a Winner in the Biotechnology Industry? - InvestorsObserver

Cellectar Biosciences Inc (CLRB) is near the top in its industry group according to InvestorsObserver. CLRB gets an overall rating of 80. That means it scores higher than 80 percent of stocks. Cellectar Biosciences Inc gets a 94 rank in the Biotechnology industry. Biotechnology is number 32 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 80 would rank higher than 80 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Cellectar Biosciences Inc (CLRB) stock is down -2.73% while the S&P 500 has risen 0.7% as of 9:45 AM on Monday, Dec 28. CLRB is lower by -$0.06 from the previous closing price of $2.20 on volume of 160,048 shares. Over the past year the S&P 500 has risen 15.76% while CLRB is lower by -5.31%. CLRB lost -$1.19 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Cellectar Biosciences Inc (CLRB) Stock.

See original here:
Is Cellectar Biosciences Inc (CLRB) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Spero Therapeutics Inc (SPRO) is near the top in its industry group according to InvestorsObserver. SPRO gets an overall rating of 73. That means it scores higher than 73 percent of stocks. Spero Therapeutics Inc gets a 88 rank in the Biotechnology industry. Biotechnology is number 29 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Spero Therapeutics Inc (SPRO) stock has gained 17.83% while the S&P 500 is down -0.12% as of 10:24 AM on Tuesday, Dec 22. SPRO is up $3.39 from the previous closing price of $19.00 on volume of 235,658 shares. Over the past year the S&P 500 has risen 14.47% while SPRO is up 114.46%. SPRO lost -$4.21 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Spero Therapeutics Inc (SPRO) Stock.

Originally posted here:
Is Spero Therapeutics Inc (SPRO) a Winner in the Biotechnology Industry? - InvestorsObserver